Skip to main content
. Author manuscript; available in PMC: 2023 Jan 14.
Published in final edited form as: Br J Haematol. 2022 Aug 27;200(2):137–149. doi: 10.1111/bjh.18418

Table 4.

Major Mutation Mechanisms of Ibrutinib Resistance

Primary Sensitivity Primary Resistance/Reduced Sensitivity Predisposition for Later Progression Secondary Resistance
CLL UM-IGHV * TP53 del/mut, complex cytogenetics
Del 18p
BTK
PLCG2
Del 8p/TRAIL-R
MCL CARD11
CCND1
TRAF2, TRAF3 & BIRC3 and MAP3K14
BTK
CCND1
CDKN2A/MTAP
DLBCL MCD or N1 molecular subtypes CARD11
TNFAIP3
KLHL14
PIM1
*

Compared to CIT, patients with CLL who have UM-IGHV do better in terms of PFS with ibrutinib-containing therapy ([128, 129]